Form 4: Lexeo Therapeutics CEO Acquires Shares via ESPP

Lexeo Therapeutics CEO Richard Nolan Townsend acquired 2,193 shares of common stock at $2.644 per share through the company's Employee Stock Purchase Plan.

Summary

• Richard Nolan Townsend, Chief Executive Officer and Director of Lexeo Therapeutics, Inc. (LXEO), acquired 2,193 shares of the company's common stock.
• The acquisition took place on September 12, 2025, at a price of $2.644 per share.
• This transaction was executed pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan.
• Following this acquisition, Townsend beneficially owns a total of 222,251 shares of common stock, which includes 131,092 Restricted Stock Units.
• The transaction is exempt from Section 16(b) liability under SEC Rules 16b-3(c) and 16b-3(d).
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The CEO's acquisition of shares through an Employee Stock Purchase Plan is a routine insider transaction, generally viewed as a minor positive signal of confidence in the company, but not a significant market-moving event.

Positives

• CEO Richard Nolan Townsend increased his direct ownership in Lexeo Therapeutics by acquiring 2,193 shares of common stock.
• Participation in the company's 2023 Employee Stock Purchase Plan demonstrates management's continued alignment with shareholder interests.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged, systematic acquisition.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction, which is specific to Lexeo Therapeutics and its CEO, and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may view the CEO's participation in the ESPP and increased ownership as a minor positive signal of management's confidence in the company's future prospects and alignment with shareholder interests.

Key Dates

Recommendation

The filing reports a routine acquisition of shares by the CEO through an Employee Stock Purchase Plan. While insider buying can be a positive signal, this specific transaction is part of a standard employee benefit program and is not indicative of a significant change in the company's fundamental outlook or a strong conviction buy/sell signal. Therefore, it does not warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

Lexeo Therapeutics, LXEO, Richard Nolan Townsend, CEO, Insider Trading, Form 4, Stock Acquisition, ESPP, Employee Stock Purchase Plan, Common Stock